LAB
Standard BioTools Inc. · Healthcare · Medical - Specialties
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.5% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 62 | -12 | 121.24M | $99.71M | +9 | −22 |
| Q1 2026 | 78 | -1 | 139.51M | $128.36M | +4 | −5 |
| Q4 2025 | 78 | +1 | 157.79M | $201.97M | +1 | — |
| Q3 2025 | 15 | 0 | 128.39M | $166.92M | — | — |
| Q2 2025 | 12 | +1 | 121.19M | $145.43M | +1 | — |
| Q1 2025 | 8 | -2 | 82.05M | $88.62M | — | −2 |
| Q4 2024 | 10 | -2 | 83.56M | $146.24M | — | −2 |
| Q3 2024 | 11 | 0 | 85.39M | $164.80M | — | — |
| Q2 2024 | 11 | — | 90.16M | $159.59M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 58.65M | 0.0% | $76.25M | 0.2% | Held | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 24.92M | +0.4% | $32.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×12 |
| 3 | The Vanguard Group ✦ (passive) | 17.25M | +1.6% | $22.42M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Geode Capital Management ✦ (passive) | 7.47M | +0.4% | $9.71M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 6.40M | +1.6% | $8.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 6.36M | — | $8.26M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 7 | ARK Investment Management ✦ | 3.02M | -4.2% | $3.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.45M | -38.4% | $1.89M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 1.30M | — | $1.68M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Citadel Advisors ✦ | 488.44K | +39.9% | $634,976 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 488.10K | -20.2% | $634,529 | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 12 | JPMorgan Chase ✦ | 250.70K | — | $325,912 | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 13 | PRIMECAP Management ✦ | 176.17K | -39.0% | $229,026 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 157.54K | -24.9% | $205,000 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 18.36K | +1.4% | $23,871 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 154 holders, 297.10M shares, $272.49M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
15.0% of class · View original SEC filing ↗
22.7% of class · View original SEC filing ↗